
XTNT Stock Forecast & Price Target
XTNT Analyst Ratings
Bulls say
Xtant Medical Holdings is well-positioned for growth and profitability in the coming years, with a diverse portfolio of orthobiologics and spinal implant products and a strong focus on the U.S. market. The recent acquisition of Dilon Technologies' HEMOBLAST Bellows product and US sales force, along with the finalization of the sale of Coflex, CoFix, and OUS business, are expected to contribute to Xtant's growth and improved financials. Despite some legacy performance challenges and the need for additional capital, the company's solid financial position and expected top-line acceleration in Orthobiologics make it a strong buy at its current valuation.
Bears say
Xtant Medical Holdings is facing various risks, including competition, legacy performance, and the need for additional capital, as well as a softer-than-expected procedure environment. The company's current capital position is also a concern, as it ended 4Q25 with only $17.3 million in cash and may require additional capital to fund operations. Additionally, with the company's expected decline in spinal implant sales and lower gross margins for FY26, it currently trades at a 1.0x discount to its peers, and we believe there is further downside potential for the stock.
This aggregate rating is based on analysts' research of Xtant Medical Holdings and is not a guaranteed prediction by Public.com or investment advice.
XTNT Analyst Forecast & Price Prediction
Start investing in XTNT
Order type
Buy in
Order amount
Est. shares
0 shares